In a report released yesterday, Allen Lutz from Bank of America Securities maintained a Buy rating on Envista Holdings, with a price target of $24.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Allen Lutz has given his Buy rating due to a combination of factors that highlight Envista Holdings’ strong performance and promising outlook. The company reported robust second-quarter results, with revenue, EBITDA, and EPS surpassing short-term estimates, indicating effective execution compared to its peers. This performance was driven by notable growth in the Specialty Products & Technologies segment, particularly in clear aligners and orthodontic products, suggesting potential market share gains.
Furthermore, Envista Holdings has revised its guidance for fiscal year 2025, projecting higher core revenue growth and adjusted EPS, which aligns with the company’s strategic goals and market expectations. The reaffirmation of EBITDA margin guidance also supports the positive outlook. The focus on orthodontic trends and market dynamics, including potential shifts in market share and profitability improvements, further underscores the rationale behind the Buy rating. Overall, these factors contribute to a favorable investment case for Envista Holdings.
Lutz covers the Healthcare sector, focusing on stocks such as Hims & Hers Health, Teladoc, and Doximity. According to TipRanks, Lutz has an average return of 4.1% and a 59.05% success rate on recommended stocks.